Who are Mictonetten 5 mg, coated tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Revefenacin 175 µg, Formoterol 20 µg, Atimos®, Umeclidinium / Vilanterol Dry Powder Inhaler, albuterol plus tiotropium, Umeclidinium/Vilanterol 62.5/25 mcgs, umeclidinium bromide and vilanterol trifenatate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mictonetten-5-mg-coated-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Mictonetten 5 mg, coated tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mictonetten 5 mg, coated tablet (Mictonetten 5 mg, coated tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimuscarinic agent. Area: Urology.

phase 3 Antimuscarinic agent M3 muscarinic receptor Urology Small molecule Live · refreshed every 30 min

Target snapshot

Mictonetten 5 mg, coated tablet (Mictonetten 5 mg, coated tablet) — APOGEPHA Arzneimittel GmbH. Mictonetten is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Mictonetten 5 mg, coated tablet TARGET	Mictonetten 5 mg, coated tablet	APOGEPHA Arzneimittel GmbH	phase 3	Antimuscarinic agent	M3 muscarinic receptor
Revefenacin 175 µg, Formoterol 20 µg	Revefenacin 175 µg, Formoterol 20 µg	University of Tennessee Graduate School of Medicine	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor; beta-2 adrenergic receptor
Atimos®	Atimos®	Chiesi Farmaceutici S.p.A.	marketed	Long-acting muscarinic antagonist (LAMA)	M3 muscarinic receptor
Umeclidinium / Vilanterol Dry Powder Inhaler	Umeclidinium / Vilanterol Dry Powder Inhaler	Gary L. Pierce	marketed	Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor; beta-2 adrenergic receptor
albuterol plus tiotropium	albuterol plus tiotropium	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	marketed	Combination bronchodilator (SABA + LAMA)	Beta-2 adrenergic receptor (albuterol); M3 muscarinic receptor (tiotropium)
Umeclidinium/Vilanterol 62.5/25 mcgs	Umeclidinium/Vilanterol 62.5/25 mcgs	National Institute of Respiratory Diseases, Mexico	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor; beta-2 adrenergic receptor
umeclidinium bromide and vilanterol trifenatate	umeclidinium bromide and vilanterol trifenatate	Chiesi Farmaceutici S.p.A.	marketed	Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor and beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimuscarinic agent class)

APOGEPHA Arzneimittel GmbH · 1 drug in this class
Alcon Labs Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mictonetten 5 mg, coated tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/mictonetten-5-mg-coated-tablet. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab